All In Biotech

Drug Trial Radar · NCT06669975

A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Dec 1, 2026

Study completion Dec 1, 2027

Sponsor

Lead sponsor
AP Biosciences Inc.Industry
Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multi-regional, multi-center, open-label, first-in-human (FIH), dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of AP402 in HER2-positive patients with locally or advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • AP402 (Part 1 Dose esclation)Drug

    Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.

  • AP402 (Part 2 Dose Expansion)Drug

    After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate of Maximum tolerated dose (MTD)Time frame: Baseline to 90 days after the last dose
  2. Number of participants with Adverse events (AEs) and Serious Adverse events (SAE) as assessed by CTCAE V5Time frame: Baseline to 90 days after the last dose
  3. To evaluate R2PD based on PK parameters- Cmax (Maximum plasma concentration)Time frame: Baseline to 90 days after the last dose
  4. To evaluate R2PD based on PK parameters- Tmax (time for maximum concentration)Time frame: Baseline to 90 days after the last dose
  5. To evaluate R2PD based on PK parameters- AUC (Area under curve)Time frame: Baseline to 90 days after the last dose
  6. To evaluate R2PD based on PK parameters- T1/2 (terminal half-life)Time frame: Baseline to 90 days after the last dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Macquarie University Clinical Trials Unit

    Macquarie, New South Wales, Australia · Not yet recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Not yet recruiting

  • Linear Clinical Research

    Perth, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.